ClinicalTrials.gg
Not yet recruitingNCT07948031LUMA-FIRSTUpdated Nov 19, 2026

Lumateperone Monotherapy Versus Usual Antidepressant Treatment for First-Episode Depression

A Phase 4 interventional study of Lumateperone and Sertraline in Major Depressive Disorder, sponsored by Sultan Qaboos University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sultan Qaboos University · Phase 4, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will compare lumateperone monotherapy with usual antidepressant treatment in adults experiencing their first lifetime episode of major depressive disorder. Use of lumateperone alone for this form of depression is investigational.

The study will enroll 134 adults aged 18 to 65 years who have clinically significant depression and have not received medication to treat their current depressive episode. Participants will be assigned by chance to one of two groups. One group will receive lumateperone 42 mg once daily as the only scheduled medicine used to treat depression. The other group will receive sertraline or escitalopram, selected by the treating psychiatrist. Treatment will last eight weeks.

Both groups will receive the same scheduled clinical contacts, information about depression, and access to psychological care. A trained assessor who does not know the assigned treatment will measure depressive symptoms at the beginning of the study and after 2, 4, and 8 weeks.

The main outcome will be improvement in depressive symptoms at week 8. Other outcomes will include response, remission, unwanted effects, stopping medication because of unwanted effects, and the need to switch or add another depression treatment. There will be weekly contact during treatment and a safety follow-up at week 10. Treatment may be changed at any time when clinically necessary. Recruitment will begin only after the required ethics and regulatory approvals have been obtained.

Read the detailed description

STUDY PURPOSE AND DESIGN This investigator-initiated, single-center, exploratory superiority trial will compare an initial treatment strategy of lumateperone monotherapy with antidepressant-based treatment as usual in first-episode major depressive disorder. Sultan Qaboos University is the sponsor. The proposed clinical site is Sultan Qaboos University Hospital, University Medical City, Muscat, Oman. The unique institutional protocol identifier is 35. The study will recruit 134 adults, with 67 assigned to each group.

The comparison concerns medication-naive patients experiencing their first lifetime depressive episode. Lumateperone monotherapy for unipolar major depressive disorder is investigational. Approval of lumateperone for other indications does not establish the benefit-risk balance of this regimen in the proposed population. The full protocol, informed consent, and local regulatory assessment will address this uncertainty and the availability of established antidepressant treatment outside the study.

DIAGNOSIS AND RECRUITMENT Diagnosis will be confirmed through a structured diagnostic assessment and a lifetime psychiatric history. Available medical records and collateral information obtained with consent will support assessment of first-episode status and exclusion of bipolar and psychotic disorders. No established antidepressant will be withdrawn solely to enable participation. Participants will be suitable for outpatient treatment and have a baseline Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 24.

RANDOMIZATION AND MASKING An independent researcher will prepare a computer-generated 1:1 allocation sequence using randomly varying balanced block sizes. An independent coordinator will retain the sequence and release allocation after eligibility, informed consent, and baseline assessments are complete. The clinician's intended usual-care antidepressant will be selected and documented before randomization for each participant.

Participants and prescribers will know the allocation. MADRS assessments will be performed by trained assessors who remain unaware of allocation and are independent of treatment decisions. Medication review and adverse-event assessment will occur separately. Participants will be asked to avoid disclosing treatment to assessors. Accidental unmasking will be documented. Treatment groups will be coded for the statistician until the primary analysis is completed.

INTERVENTIONS The experimental group will receive lumateperone 42 mg orally once daily in the evening, with or without food, for eight weeks. No antidepressant, additional antipsychotic, or mood stabilizer will be routinely prescribed with lumateperone to treat depression. Routine dose titration or an alternative lower-dose efficacy regimen is not planned. Temporary interruption or discontinuation will be permitted when clinically indicated.

The comparator group will receive either sertraline or escitalopram, selected according to clinical suitability, patient preference, and contraindications. Sertraline will usually start at 50 mg daily, with clinician-directed adjustment within 50 to 200 mg daily. Escitalopram will usually start at 10 mg daily, with adjustment up to 20 mg daily when appropriate. Lower starting doses and product-specific dose restrictions will be observed when clinically indicated. Both medicines will not be assigned together as the planned comparator treatment. Prescribing will follow the locally authorized product information and pharmacy review.

Both groups will receive comparable clinical contact, psychoeducation, adherence support, and access to psychological care. Psychological treatments and all relevant concomitant medicines will be recorded. Clinically necessary treatment changes and rescue interventions will remain available in both groups.

ASSESSMENTS Clinic assessments will take place at baseline and weeks 2, 4, and 8. Telephone or video safety contacts will occur at weeks 1, 3, 5, 6, and 7. A final scheduled safety contact will occur at week 10. Additional contact will be arranged when needed. MADRS ratings will be collected at baseline and weeks 2, 4, and 8. The same language version will be used throughout follow-up. Rater training and access to the approved Arabic and English instruments will be arranged before recruitment.

The primary outcome is change in MADRS score from baseline to week 8. Secondary outcomes are response, remission, treatment-emergent adverse events, discontinuation of the initial medication because of adverse effects, and use of rescue treatment. Participants who discontinue or change medication will be encouraged to remain in follow-up.

SAFETY AND RESCUE TREATMENT Baseline assessment will include medical and psychiatric history, medication reconciliation, weight, vital signs, appropriate laboratory testing, electrocardiography, and pregnancy testing when applicable. The full protocol will specify laboratory assessments and stopping rules before recruitment. Safety reviews will address suicidal thoughts and behavior, emerging mania or hypomania, sedation, dizziness, orthostatic symptoms, akathisia, other abnormal movements, and metabolic changes. Glucose, lipid, and weight monitoring will be included.

Urgent reassessment will be arranged for suicidal intent, mania, psychosis, substantial deterioration, serious adverse reactions, or inability to remain safely in outpatient care. Established treatment will not be delayed to preserve the assigned regimen. At week 4, persistent clinically significant symptoms with less than 20% MADRS improvement will trigger senior psychiatric review and a discussion of optimization or rescue treatment. This is a proposed study decision rule and does not restrict earlier clinical intervention.

An independent safety physician will review serious or unexpected events. Formal monitoring arrangements and the need for a data monitoring committee will be agreed with the sponsor and ethics committee. Serious adverse events will be reported according to institutional and regulatory requirements. Ongoing adverse events will be followed to resolution or clinical stabilization, including after week 10 when necessary.

At week 8, ongoing clinical treatment will be agreed with each participant and the treating psychiatrist. Appropriate access to continuing treatment or a supervised transition to another treatment must be arranged before recruitment. Finishing the research assessments will not automatically end clinical care.

SAMPLE SIZE The target is 134 randomized participants, with 67 per group. A two-sided independent two-sample calculation with alpha 0.05 and 80% power requires approximately 53 evaluable participants per group to detect a standardized difference of 0.55. Allowance for approximately 20% unavailable primary outcomes gives 67 participants per group. The assumed difference is a planning value and has not been established for lumateperone monotherapy against active antidepressant care in first-episode depression. The study is exploratory and is not designed to demonstrate noninferiority or equivalence. A nonsignificant difference will not establish comparable efficacy.

STATISTICAL ANALYSIS The primary analysis will follow the intention-to-treat principle. Week-8 MADRS scores will be compared using analysis of covariance adjusted for baseline MADRS score. The adjusted between-group difference, 95% confidence interval, and two-sided p value will be reported. A significance level of 0.05 will apply to the primary outcome.

Data collected after medication discontinuation, switching, or rescue treatment will remain part of the primary analysis. The estimand is the effect of assignment to the two initial treatment strategies under the trial's clinical management arrangements. Missing primary outcomes will be addressed by multiple imputation under a missing-at-random assumption, including allocation, baseline severity, available intermediate scores, and relevant predictors of missingness. Complete-case and missing-not-at-random sensitivity analyses will be prespecified in the statistical analysis plan.

Response, remission, rescue treatment, and discontinuation will be reported as proportions with between-group differences and confidence intervals. Secondary analyses will be exploratory. Any supplementary analysis restricted to participants who maintained the assigned regimen will be interpreted cautiously because remaining on treatment is affected by response and tolerability. No interim efficacy analysis is planned.

MEDICATION SUPPLY AND APPROVALS Lumateperone is planned to be purchased from Johnson \& Johnson or an authorized supplier, subject to availability, procurement arrangements, and applicable permissions in Oman. This is a planned purchase rather than a confirmed supply, funding, or collaboration agreement. Johnson \& Johnson is not listed as a sponsor or collaborator on the basis of the planned purchase alone. Pharmacy will manage receipt, storage, dispensing, and accountability.

Ethics review has not yet been requested. Recruitment will begin only after ethics approval and all required institutional and regulatory permissions are in place. Registration does not constitute permission to start the trial.

02

Conditions studied

  • Major Depressive Disorder

Keywords

  • Lumateperone
  • Caplyta
  • Monotherapy
  • First-episode depression
  • Antidepressant treatment
  • Randomized controlled trial
  • Oman
03

In context

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

This study's planned enrollment of 134 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

Sultan Qaboos University is the lead sponsor of 51 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 65 years and ability to provide written .
  2. First lifetime major depressive episode meeting criteria for major depressive disorder without psychotic features, confirmed by a structured diagnostic assessment.
  3. MADRS total score of at least 24 at screening and baseline.
  4. No previous pharmacological treatment for the current depressive episode and no current antidepressant, antipsychotic, or mood-stabilizing medication.
  5. Clinical suitability for outpatient treatment and for either randomized treatment strategy.
  6. Ability to complete assessments in Arabic or English, using the same language throughout follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Any previous lifetime major depressive episode.
  2. History of mania, hypomania, bipolar disorder, schizophrenia-spectrum disorder, or another primary psychotic disorder.
  3. Current depressive episode with psychotic features, mixed features, or catatonia.
  4. Immediate suicide risk or another condition requiring urgent inpatient treatment, electroconvulsive therapy, or an intervention incompatible with randomization.
  5. Substance-induced depression, depression attributable to another medical condition, or an active substance use disorder that would interfere with treatment or assessment.
  6. A psychiatric or medical condition requiring continuation or immediate initiation of medication incompatible with either assigned treatment strategy.
  7. to lumateperone or its formulation; moderate or severe hepatic impairment; or a moderate or strong inhibitor or a CYP3A4 inducer incompatible with the fixed 42 mg lumateperone regimen. to both proposed usual-care antidepressants also exclude participation.
  8. unstable medical illness or electrocardiographic abnormalities that make participation unsafe.
  9. Pregnancy, breastfeeding, planned pregnancy during the trial, or inability to meet the pregnancy-testing and reproductive-safety requirements approved in the full protocol.
  10. Participation in another interventional study that could affect treatment or outcome assessment.
  11. Inability to provide or complete essential study procedures.

Stable anxiety disorders and stable medical comorbidities may be permitted when diagnosis, safety, and assessment are not compromised. Passive suicidal thoughts require individualized assessment and do not automatically exclude an otherwise safe outpatient participant. No established treatment will be stopped solely to permit enrollment.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Lumateperone Monotherapy

    Participants will receive lumateperone 42 mg orally once daily in the evening for eight weeks. It will be the only scheduled medicine used to treat depression. No antidepressant, additional antipsychotic, or mood stabilizer will be routinely added. Both groups will receive comparable clinical reviews, psychoeducation, and access to psychological care. Interruption, discontinuation, or rescue treatment will be allowed when clinically required. Starting another depression treatment will be recorded as rescue treatment and a departure from the assigned monotherapy regimen. Outcome follow-up will continue whenever consent permits.

    Drug: Lumateperone

  • Active comparator
    Antidepressant-Based Treatment as Usual

    Participants will receive either sertraline or escitalopram selected by their psychiatrist. The intended usual-care antidepressant will be documented before randomization. Treatment will be adjusted according to response, tolerability, contraindications, and locally authorized prescribing information. Both groups will receive comparable clinical reviews, psychoeducation, and access to psychological care. Clinically necessary treatment changes and rescue interventions will be permitted and recorded.

    Drug: Sertraline · Drug: Escitalopram

Interventions

  • DrugLumateperone

    Lumateperone (Caplyta) 42 mg orally once daily in the evening, with or without food, for eight weeks as pharmacological monotherapy for depression. Routine titration or escalation is not planned. Participants requiring an alternative dose for hepatic impairment or interacting medication will be excluded from this fixed-dose study. Temporary interruption or discontinuation is permitted for safety or intolerance.

  • DrugSertraline

    One of the two usual-care alternatives. Sertraline will usually be started at 50 mg orally once daily and adjusted by the treating psychiatrist within 50 to 200 mg daily according to response and tolerability. A lower starting dose may be used when clinically indicated. Dosing will follow locally authorized product information and pharmacy review. It is an alternative to escitalopram, rather than a planned combination.

  • DrugEscitalopram

    One of the two usual-care alternatives. Escitalopram will usually be started at 10 mg orally once daily and may be adjusted up to 20 mg daily when clinically appropriate. Lower starting doses or maintenance limits will follow age, comorbidity, tolerability, locally authorized product information, and pharmacy review. It is an alternative to sertraline, rather than a planned combination.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale Total Score at Week 8

    The Montgomery-Asberg Depression Rating Scale (MADRS) contains 10 clinician-rated items, each scored from 0 to 6. Total scores range from 0 to 60; higher scores indicate greater depressive symptom severity. A trained assessor unaware of allocation will administer the scale. Change is the week-8 score minus the baseline score, with negative values indicating improvement. The primary comparison is the baseline-adjusted between-group difference.

    Time frame: Baseline and week 8

Secondary outcomes

  1. Proportion of Participants Achieving Depression Response

    Response is defined as a reduction of at least 50% from baseline in the MADRS total score. MADRS scores range from 0 to 60, with higher scores indicating greater depressive symptom severity.

    Time frame: Week 8

  2. Proportion of Participants Achieving Depression Remission

    Remission is defined as a MADRS total score of 10 or lower at week 8. MADRS scores range from 0 to 60, with higher scores indicating greater depressive symptom severity.

    Time frame: Week 8

  3. Number of Participants With at Least One Treatment-Emergent Adverse Event

    A treatment-emergent adverse event is a new medical or psychiatric event, or worsening of a pre-existing condition, after initiation of the assigned medication. Events will be collected in both groups by structured questioning, clinical review, and relevant medical records. Severity, seriousness, suspected relatedness, and management will be recorded. Ongoing events will continue to receive clinical follow-up when necessary.

    Time frame: From the first dose through week 10

  4. Number of Participants Discontinuing the Initially Assigned Medication Because of Adverse Effects

    Permanent discontinuation of lumateperone or the initially selected antidepressant because of an adverse effect will be recorded. The medication, reason, and date will be documented. Temporary interruptions will be recorded separately and will not count as permanent discontinuation.

    Time frame: From treatment initiation through week 8

  5. Number of Participants Receiving Rescue Treatment

    Rescue treatment is the initiation of an additional treatment for depression or switching the initially assigned medication because of inadequate benefit, deterioration, or intolerance. Hospitalization, electroconvulsive therapy, and other urgent interventions will also be recorded when applicable. Dose adjustment of the initially assigned medication alone will not count as rescue treatment. Indication and timing will be documented.

    Time frame: From randomization through week 8

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for May 2030, 35 months later.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 35 months is below that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Jun 2027
Primary completionEst.
May 2030
CompletionEst.
Jun 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948031
Lead sponsor
Sultan Qaboos University
Responsible party
Mohammed Al Alawi MD PhD MRCPsych ARABpsych OMSBpsych (Assistant Professor and Senior Consultant, Sultan Qaboos University) — Principal investigator
First posted
Nov 19, 2026
Start date
Jun 2027 (estimated)
Primary completion
May 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Mohammed Al Alawi, MD, PhD, MBA, MRCPsych
Contact
m.alalawi2@squ.edu.om
+96824141511
Mohammed Al Alawi, MD, PhD, MBA, MRCPsych
principal investigator · Sultan Qaboos University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion